Literature DB >> 12727274

The in vitro effects of two chirodropid (Chironex fleckeri and Chiropsalmus sp.) venoms: efficacy of box jellyfish antivenom.

Sharmaine Ramasamy1, Geoff K Isbister, Jamie E Seymour, Wayne C Hodgson.   

Abstract

The pharmacological and biochemical isolation of cnidarian venoms has been hindered by difficulties with both extracting pure venom from nematocysts and venom stability. The development of a new technique to extract active, pure venom of Chironex fleckeri and Chiropsalmus sp. has enabled identify both neurotoxic and myotoxic activity in their venoms. These activities are similar, but not identical in each species. Venom (50 micro g/ml) from both species significantly inhibited indirect and direct twitches of the chick biventer nerve-muscle preparation. Pre-incubation with 1U/ml box jellyfish antivenom did not have any significant effect on venom-induced reductions of indirect twitches. However, this activity was markedly attenuated by prior addition of 5U/ml antivenom, albeit to a lesser degree for Chiropsalmus sp. In contrast, prior addition of 5U/ml box jellyfish antivenom did not neutralise the myotoxic activity of C. fleckeri venom (50 micro g/ml), although it did inhibit the myotoxicity produced by Chiropsalmus sp. venom (50 micro g/ml). Antivenom (5U/ml) added 1h after the addition of C. fleckeri venom (50 micro g/ml) had no effect on the indirect or direct twitches of the skeletal muscle preparation. However, it partially restored the reduction in indirect twitch height caused by Chiropsalmus sp. venom (50 micro g/ml). Myotoxicity was confirmed in muscle preparations stained with hematoxylin and eosin.Therefore, although antivenom was able to neutralize the neurotoxic effects of both species, and the myotoxic effects of Chiropsalmus sp., when added prior to venom, it was unable to reverse the effects after venom addition. This suggests that antivenom is unlikely to be useful in the treatment of neurotoxic or myotoxic effects in patients, although these effects are rarely seen clinically.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12727274     DOI: 10.1016/s0041-0101(03)00046-1

Source DB:  PubMed          Journal:  Toxicon        ISSN: 0041-0101            Impact factor:   3.033


  8 in total

Review 1.  Immunological and toxinological responses to jellyfish stings.

Authors:  James Tibballs; Angel A Yanagihara; Helen C Turner; Ken Winkel
Journal:  Inflamm Allergy Drug Targets       Date:  2011-10

Review 2.  Jellyfish stings and their management: a review.

Authors:  Luca Cegolon; William C Heymann; John H Lange; Giuseppe Mastrangelo
Journal:  Mar Drugs       Date:  2013-02-22       Impact factor: 5.118

3.  Pharmacological studies of tentacle extract from the jellyfish Cyanea capillata in isolated rat aorta.

Authors:  Beilei Wang; Bo Zhang; Qianqian Wang; Zhi Zhang; Fei Nie; Guoyan Liu; Jiemin Zheng; Liang Xiao; Liming Zhang
Journal:  Mar Drugs       Date:  2013-08-30       Impact factor: 5.118

Review 4.  Ancient Venom Systems: A Review on Cnidaria Toxins.

Authors:  Mahdokht Jouiaei; Angel A Yanagihara; Bruno Madio; Timo J Nevalainen; Paul F Alewood; Bryan G Fry
Journal:  Toxins (Basel)       Date:  2015-06-18       Impact factor: 4.546

Review 5.  The pathology of Chironex fleckeri venom and known biological mechanisms.

Authors:  Melissa Piontek; Jamie E Seymour; Yide Wong; Tyler Gilstrom; Jeremy Potriquet; Ernest Jennings; Alan Nimmo; John J Miles
Journal:  Toxicon X       Date:  2020-02-24

Review 6.  A Review of Toxins from Cnidaria.

Authors:  Isabella D'Ambra; Chiara Lauritano
Journal:  Mar Drugs       Date:  2020-10-06       Impact factor: 5.118

7.  Dose and time dependence of box jellyfish antivenom.

Authors:  Athena Andreosso; Michael J Smout; Jamie E Seymour
Journal:  J Venom Anim Toxins Incl Trop Dis       Date:  2014-08-12

Review 8.  Biotechnological Applications of Scyphomedusae.

Authors:  Louise Merquiol; Giovanna Romano; Adrianna Ianora; Isabella D'Ambra
Journal:  Mar Drugs       Date:  2019-10-24       Impact factor: 5.118

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.